Megakaryopoiesis and platelet function in polycythemia vera and essential thrombocythemia patients with JAK2 V617F mutation

International Journal of Hematology

Volumn 88, Issue 2, 2008, Pages 181-188

  Hattori, Norimichi ^a   Fukuchi, Kunihiko ^a   Nakashima, Hidetoshi ^a   Maeda, Takashi ^a   Adachi, Daisuke ^a   Saito, Bungo ^a   Yanagisawa, Kouji ^a   Matsuda, Isao ^a   Nakamaki, Tsuyoshi ^a   Gomi, Kunihide ^a   Tomoyasu, Shigeru ^a  

^a SHOWA UNIVERSITY   (Japan)

Author keywords

JAK2 V617F; Megakaryopoiesis; Mutation specific PCR; ph chromosome negative myeloproliferative disease; Thromboelastography

Indexed keywords

JANUS KINASE 2;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HYPERCOAGULABILITY; MALE; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MYELOID METAPLASIA; PHILADELPHIA CHROMOSOME NEGATIVE CELL; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTHEMIA; THROMBOELASTOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; BLOOD PLATELETS; BONE MARROW CELLS; DISEASE PROGRESSION; FEMALE; HEMATOPOIESIS; HUMANS; JANUS KINASE 2; MALE; MEGAKARYOCYTES; MIDDLE AGED; PHILADELPHIA CHROMOSOME; POINT MUTATION; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; THROMBELASTOGRAPHY; THROMBOCYTHEMIA, ESSENTIAL;

EID: 56649086749     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-008-0129-9     Document Type: Article

References (38)

1. EJ Baxter LM Scott PJ Campbell 2005 Aquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders Lancet 365 1054 61
2. RL Levine M Wadleigh J Cools 2005 Activation mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis Cancer Cell 7 387 97
3. C James V Ugo JP Le Couedic 2005 A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera Nature 434 1144 8
4. R Kralovics F Passamonti AS Buser 2005 A gain-of-function mutation of JAK2 in myeloproliferative disorder N Engl J Med 352 1779 90
5. RA Mesa S Verstovsek F Cervantes 2007 Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT) Leuk Res 31 737 40
6. A Tefferi J Thiele A Orazi 2007 Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel Blood 110 1092 7
7. JJ Michiels H De Raeve K Hebeda 2007 WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders Leuk Res 31 1031 8
8. JJ Michiels H De Raeve Z Berneman 2006 The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders Semin Thromb Hemost 32 307 40
9. LM Scott MA Scott PJ Campbell AR Green 2006 Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia Blood 108 2435 7
10. CH Jamieson J Gotlib JA Durocher 2006 The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation Proc Natl Acad Sci USA 103 6224 9
11. E Lippert M Boissinot R Kralovics 2006 The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera Blood 108 1865 7
12. S Dupont A Massé C James 2007 The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera Blood 110 1013 21
13. G Wernig T Mercher R Okabe RL Levine BH Lee DG Gilliland 2006 Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model Blood 107 4274 81
14. TG Bumm C Elsea AS Corbin 2006 Characterization of murine JAK2V617F-positive myeloproliferative disease Cancer Res 66 11156 65
15. C Lacout DF Pisani M Tulliez FM Gachelin W Vainchenker JL Villeval 2006 JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis Blood 108 1652 60
16. VM Zaleskas DS Krause K Lazarides 2006 Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F PLos ONE 1 e18
17. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds.). World Health Organization classification of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001, p. 15-44.
18. EW Salzman 1963 Measurement of platelet adhesiveness: a simple in vitro technique demonstrating an abnormality in von Willebrand's disease J Lab Clin Med 62 724 35
19. GVR Born 1962 Aggregation of blood platelets by adenosine diphosphate and its reversal Nature 194 927 9
20. PA Castaldi MC Rozenberg JH Stewart 1966 The bleeding disorder of uremia: a qualitative platelet defect Lancet 2 66 9
21. Sambrook J, Russell D. Molecular cloning: a laboratory manual. New York: Cold Spring Harbor Laboratory Press; 2001.
22. K Fukuchi K Nakamura S Ichimura 2003 The association of cyclin A and cyclin kinase inhibitor p21 in response to gamma-irradiation requires the CDK2 binding region, but not the Cy motif Biochim Biophys Acta 1642 163 71
23. J Jelinek Y Oki V Gharibyan 2005 JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia Blood 106 3370 3
24. DP Steensma GW Dewald TL Lasho 2005 The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes Blood 106 1207 9
25. Tefferi A, Gilliland DG. Oncogenes in myeloproliferative disorders. Cell Cycle. 2007:550-66.
26. Z Rudzki T Sacha A Stoj 2007 The gain of function JAK2 V617F mutation shifts the phenotype of essential thrombocythaemia and chronic idiopathic myelofibrosis to more "erythremic" and less "throbocythemic" : a molecular, histologic, and clinical study Int J of Hematol 86 130 6
27. AP Wolanskyj TL Lasho SM Schwager 2005 JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance Br J Haematol 131 208 13
28. PJ Campbell LM Scott G Buck 2005 Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study Lancet 366 1945 53
29. Antonioli E, Guglielmelli P, Poli G, et al. Myeloproliferative Disorders Research Consortium (MPD-RC). Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica. 2008;93:41-8.
30. F Delhommeau DF Pisani C James N Casadevall S Constantinescu W Vainchenker 2006 Oncogenic mechanisms in myeloproliferative disorders Cell Mol Life Sci 63 2939 53
31. PJ Van Genderen JJ Michiels R Van Strik J Lindemans HH van Vliet 1995 Platelet consumption in thrombocythemia complicated by erythromelalgia: reversal by aspirin Thromb Haemost 73 210 4
32. M Samoszuk M Corwin SL Hazen 2003 Effects of human mast cell tryptase and eosinophil granule proteins on the kinetics of blood clotting Am J Hematol 73 18 25
33. RC Carroll RM Craft JJ Chavez CC Snider SJ Bresee E Cohen 2005 A thrombelastograph whole blood assay for clinical monitoring of NSAID-insensitive transcellular platelet activation by arachidonic acid J Lab Clin Med 146 30 5
34. A Falanga M Marchetti A Vignoli D Balducci T Barbui 2005 Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera Exp Hematol 33 523 30
35. RA Mesa DS Nagorney S Schwager J Allred A Tefferi 2006 Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic Cancer 107 361 70
36. Landolfi R, Di Gennaro L, Barbui T, et al. European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP). Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood. 2007;109:2446-52.
37. A Carobbio G Finazzi V Guerini 2007 Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status Blood 109 2310 3
38. AD Pardanani RL Levine T Lasho 2006 MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1,182 patients Blood 108 3472 6